Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 7/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010469 | 0.87 | IKBKB (0.36) | YTHDC1P2RY1IKBKBCHUKNPC1 | |
| SCHEMBL18175167 | 0.84 | LMNA (0.37) | YTHDC1P2RY1IKBKBCHUK | |
| SCHEMBL10280149 | 0.83 | TRPA1 (0.36) | YTHDC1P2RY1IKBKBCHUK | |
| SCHEMBL6092162 | 0.81 | APOBEC3A (0.36) | YTHDC1NPC1RAB9APLK1 | |
| SCHEMBL19036512 | 0.80 | P2RY1 (0.37) | YTHDC1P2RY1IKBKBCHUK | |
| SCHEMBL29188197 | 0.79 | POLB (0.41) | P2RY1 | |
| SCHEMBL27967273 | 0.78 | KMT2A (0.42) | YTHDC1P2RY1IKBKBCHUK | |
| SCHEMBL20079775 | 0.77 | PTGS2 (0.43) | — | |
| SCHEMBL20079735 | 0.71 | POLB (0.48) | NPC1RAB9A | |
| SCHEMBL20161992 | 0.71 | PDE10A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | YTHDC1 4155/4885P2RY1 1600/4885IKBKB 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.